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Abstract
Nicotinamide adenine dinucleotide (NAD+) synthetase catalyzes the last step in NAD+ 
biosynthesis. Depletion of NAD+ is bactericidal for both active and dormant Mycobacterium 
tuberculosis (Mtb). By inhibiting NAD+ synthetase (NadE) from Mtb, we expect to eliminate 
NAD+ production which will result in cell death in both growing and nonreplicating Mtb. NadE 
inhibitors have been investigated against various pathogens, but few have been tested against Mtb. 
Here, we report on the expansion of a series of urea-sulfonamides, previously reported by 
Brouillette et al. Guided by docking studies, substituents on a terminal phenyl ring were varied to 
understand the structure-activity-relationships of substituents on this position. Compounds were 
tested as inhibitors of both recombinant Mtb NadE and Mtb whole cells. While the parent 
compound displayed very weak inhibition against Mtb NadE (IC50 = 1000 μM), we observed up to 
a 10-fold enhancement in potency after optimization. Replacement of the 3,4-dichloro group on 
the phenyl ring of the parent compound with 4-nitro yielded 4f, the most potent compound of the 
series with an IC50 value of 90 μM against Mtb NadE. Our modeling results show that these urea-
sulfonamides potentially bind to the intramolecular ammonia tunnel, which transports ammonia 
from the glutaminase domain to the active site of the enzyme. This hypothesis is supported by data 
showing that, even when treated with potent inhibitors, NadE catalysis is restored when treated 
with exogenous ammonia. Most of these compounds also inhibited Mtb cell growth with MIC 
values of 19-100 μg/mL. These results improve our understanding of the SAR of the urea-
sulfonamides, their mechanism of binding to the enzyme, and of Mtb NadE as a potential 
antitubercular drug target.
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Tuberculosis (TB), caused by the bacillus Mycobacterium tuberculosis (Mtb), remains one 
of the world's deadliest infectious diseases.1-3 According to the World Health Organization 
(WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS), 10.4 million 
people fell ill and 1.8 million died from TB in 2015, which is 0.7 million more than those 
who died from HIV-related illnesses.1, 2 Besides the high prevalence of TB, the large 
number of new cases of multi-drug resistant (MDR) and extensively-drug resistant (XDR) 
TB has made the disease a more serious public health concern.2 Two of the most important 
first-line TB drugs (isoniazid, rifampicin) are both ineffective against MDR-TB and XDR-
TB, rendering the treatment options very limited.4, 5 Thus, there remains a pressing need for 
novel drugs that shorten TB treatment and are effective against all pathogenic strains.
Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous enzyme cofactor, indispensable 
for reduction-oxidation reactions as well as essential nonredox functions in the cell such as 
cell longevity, telomere maintenance, Ca2+ signaling, DNA repair, and immune response.6, 7 
NAD+ synthetase (NadE) is an essential enzyme that catalyzes the last step in many NAD+ 
de novo biosynthesis and NAD+ recycling pathways.8, 9 In Mtb, NadE transforms nicotinic 
acid adenine dinucleotide (NaAD+) into NAD+ via a two-step process with the assistance of 
ATP and ammonia (Figure 1).8-13 Ammonia is obtained from glutamine hydrolysis in the 
glutaminase domain of the enzyme.8-13 Inhibition of NadE blocks NAD+ biosynthesis and 
leads to cell death in both growing and nonreplicating Mtb.14-16 The importance of NAD+ 
encourages the design of NadE inhibitors that may be effective against both active and latent 
tuberculosis. Moreover, the low sequence identity of 23% between Mtb NadE and the 
human homolog, as well as the presence of NadE-independent NAD+ biosynthesis pathways 
in humans, increases the attraction of NadE as a drug target for Mtb.7, 13, 17, 18
Despite this promise, few studies explore NadE inhibitors as antitubercular agents. Velu et 
al. reported a series of tethered dimers as inhibitors of B. subtilis NadE and several Gram-
positive organisms.16, 19 One of the most potent B. subtilis NadE inhibitors from this work 
(Figure 2A) yielded an IC50 (concentration resulting in 50% enzyme inhibition) value of 10 
μM against B. subtilis NadE and an MIC (minimum inhibitory concentration) of 1.5 μM 
against B. subtilis.16, 19 Boshoff et al. tested several of these tethered dimers against Mtb 
NadE and Mtb cellular growth.14 The compounds, however, showed only modest activity. 
The most potent Mtb NadE inhibitor (Figure 2B) gave an IC50 of 21.8 μM against Mtb NadE 
and an Mtb MIC of 20 μM.14
A significant number of compounds as inhibitors of NadE have been synthesized by the 
Brouillette group.20, 21 Using a high-throughput assay, they discovered compound 5824, 
which showed strong inhibition of B. anthracis NadE (IC50 = 6.4 μM, Figure 2).20 
According to their modeling results using the B. subtilis homolog, the group predicted that 
5824 bound to the NaAD+ subsite of NadE.20 The group next reported a series of the reverse 
sulfonamide analogs of 5824 that were tested against B. anthracis NadE, B. anthracis 
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NaMNAT, and B. anthracis Sterne. One of their best inhibitors (Figure 2C) displayed a B. 
anthracis NadE IC50 of 15.3 μM but did not kill B. anthracis cells.21
In order to evaluate compounds that are active against Bacillus NadE as potential Mtb NadE 
inhibitors, the similarity between Bacillus and Mtb homologs was explored. Mtb NadE is 
glutamine dependent and has a glutaminase domain that transports ammonia to the 
synthetase domain via an ammonia tunnel.11 Interestingly, NadE from B. subtilis or B. 
anthracis depends on exogenous ammonia and does not possess a glutaminase domain or an 
ammonia tunnel.22, 23 Thus, the amino acid sequences of NadE from B. subtilis, B. 
anthracis, and only the C-terminal domain of Mtb NadE (i.e., the Mtb NadE synthetase 
domain that is homologous to the Bacillus NadE enzymes) were aligned. The sequence 
identity among these enzymes was calculated based on this alignment using MUSCLE24, 25 
(Table 1). While the two Bacillus NadEs share 88.6% sequence identity, the Mtb NadE C-
terminal domain shares 36.6% sequence identity to the Bacillus subtilis NadE and 34.4% 
sequence identity to the Bacillus anthracis NadE. We expected high conservation of the 
active site residues between species, which encourages the design of Mtb NadE inhibitors 
based on the Bacillus inhibitor structures. Therefore, we chose compound 5824 (3-{4-[(3,4 
dichlorophenyl)sulfamoyl]phenyl}-1-(4-nitrophenyl)urea, Figure 2) as the parent structure 
for the current work.
A virtual library of 118 urea-sulfonamide analogs was made. Half of the compounds were 
sulfonamides, retaining the configuration of parent compound 5824, while half were the 
‘reversed sulfonamide’, corresponding to the opposite configuration. Compounds varied 
structurally only at ring A, where a variety of substituents were appended. Substituents were 
selected based on the Topliss approach toward aromatic systems26 as well as commercially 
available anilines. Compounds were docked into the crystal structure of Mtb NadE13 (PDB 
id: 3DLA) using the Glide tool in Schrodinger, suite 201027. The 100 top-scoring analogs 
are shown in Table S1 (more negative Glide scores predicting improved binding affinities). 
Interestingly, the putative binding site of many analogs was predicted to involve the 
intramolecular ammonia tunnel11 that transports ammonia from the glutaminase domain to 
the synthetase domain (Table S2). For example, compound 4l (R = 4-H) formed hydrogen 
bonds with GLY-366 and LEU-399 (Figure 3A), and ring A rested in a hydrophobic pocket, 
the entrance to the tunnel (Figure 3B). Based on these modeling results and synthetic 
feasibility, a series of analogs was selected for synthesis (Figure 4). These compounds could 
shed light on the influence of ring A structural changes on Mtb NadE inhibition and 
antibacterial activity.
To prepare the desired compounds, a simple synthetic route was designed (Scheme 1). 
Substituted anilines 1a-l were combined with 4-acetamidobenzenesulfonyl chloride to obtain 
compounds 2a-l generally in high yield unless a second recrystallization in ethanol was 
needed. The deacetylated products (3a-l) were obtained after acid hydrolysis and were 
purified either by silica column chromatography or recrystallization. The intermediates 3a-l 
were then combined with 4-nitrophenylisocyanate to yield final compounds 4a-l. Due to 
production of a sticky side product (likely a urea), purification of some final compounds 
proved challenging. Such reactions were purified by silica column chromatography and then 
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by recrystallization from acetone to achieve high purity but with substantially reduced 
yields28-31
Compounds were evaluated for inhibition of Mtb NadE measuring their effect on 
pyrophosphate (PPi) production using the EnzChek Pyrophosphate Assay (ThermoFisher, 
Waltham, MA). Briefly, PPi formation is coupled to the production of 2-amino-6-
mercapto-7-methylpurine at 360 nm. The IC50 values are shown in Table 2. The synthesized 
urea-sulfonamide compounds show a 10-fold range of activity against Mtb NadE. Parent 
compound 4i (5824) shows poor inhibition of Mtb NadE (IC50 = 1000 ± 300 μM), contrary 
to its more potent inhibition of B. anthracis NadE (IC50 = 6.4 μM).21 This difference in 
efficacy is likely due to structural differences between the two homologs (as noted above). 
Our modeling results show that the binding site of this series of compounds may involve the 
intramolecular ammonia tunnel of the Mtb NadE. This tunnel is absent in B. subtilis and B. 
anthracis. Thus, compound 4i likely binds to an alternate site in the Bacillus homologs 
compared with Mtb NadE.
The new analogs show improved Mtb NadE inhibition relative to the parent compound with 
most IC50 values roughly 5-10-fold better than 4i. The most potent Mtb NadE inhibitor of 
the series is 4f (4-NO2) with an IC50 value of 90 μM. Comparing unsubstituted analog 41 
with other analogs in the series, halogen-substituents are generally not beneficial in terms of 
Mtb NadE inhibition as compounds 4e, 4j, and 4k were among the least potent of the series. 
The remaining analogs, 4a-d and 4f-h have similar activities compared to unsubstituted 
compound 4l and yield a bland structure-activity-relationship profile between these 
substituents and Mtb NadE inhibition.
To further investigate the binding mechanism of this series of compounds, an ammonia-
dependent Mtb NadE inhibition assay12, 32 was performed on the most potent compounds 
4d, 4f, 4h and 4l. In this assay, exogenous ammonia is used as the ammonia source for the 
NadE reaction, as opposed to the ammonia synthesized by the glutaminase domain of the 
enzyme. As shown in Table 2, these compounds lose inhibition (IC50 >200 μM) against Mtb 
NadE when exogenous ammonia is supplied, and enzymatic activity is restored. This 
supports our hypothesis that these compounds bind to the intramolecular ammonia tunnel 
suggested from the modeling study, as well as offering an explanation of the activity 
difference observed for compound 4i against B. anthracis NadE versus Mtb NadE.
The urea-sulfonamides were also tested for the inhibition of Mtb cellular growth in both rich 
media (7H9) and minimal media (GAST-Fe).33-36 The antitubercular activities of these 
compounds are shown in Table 2. All compounds inhibit Mtb growth to a moderate extent 
with MIC values of 19-100 μg/mL (7H9). The most potent compound is 4e (4-F) with an 
MIC value of 19 μg/mL (7H9). Again, the structure-activity relationship of the series is flat, 
indicating this portion of the urea-sulfonamides does not impact antitubercular activities to a 
great extent.
There remains an urgent need for antitubercular drugs that are highly active and work 
through new modes of actions. This work builds on the novel design of three-ring urea-
sulfonamides as NadE inhibitors. The parent compound 4i, shows very different potency 
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against Mtb and B. anthracis NadE homologs, perhaps due to structural differences between 
the two enzymes. This is supported by our preliminary modeling studies, showing that the 
binding sites of these compounds may overlap with the ammonia tunnel in Mtb NadE rather 
than the NaAD+ subsite in B. anthracis NadE20, as suggested earlier. This hypothesis is 
reinforced by the loss of activities for the active Mtb NadE inhibitors when treated with 
exogenous ammonia instead of that from glutamine. This point of difference may be used to 
design selective inhibitors targeting Mtb NadE over other homologs. While most of the 
analogs display a 5-10-fold improvement against Mtb NadE over the parent compound, all 
of the compounds show moderate activity against Mtb whole cell growth. Structural 
optimization of these compounds is needed, not only to improve activity against both Mtb 
NadE and Mtb, but also to increase solubility which was noticeably poor in various organic 
solvents and water. Such compounds would aid in further validating NadE as an effective 
target for Mtb and other bacterial pathogens.
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28. Compound 4e. To a solution of the 3e (1 eq) in anhydrous THF (30 mL/mmol) was added 4-
nitrophenylisocyanate (1 eq). The reaction mixture was stirred at room temperature overnight, 
concentrated. Silica cake was prepared in acetone and chromatographic separation on silica gel 
(EtOAc/CH2Cl2 = 1/30 to 1/5) gave the crude solids which were further recrystallized in acetone 
to give the expected compound as white solids. Yield: 14%. 1H NMR (acetone-d6, 400 MHz), δ 
(ppm): 6.99-7.07 (m, 2H), 7.20-7.25 (m, 2H), 7.63-7.71 (m, 4H), 7.76-7.81 (m, 2H), 8.17-8.23 (m, 
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146.83, 152.62, 159.79, 162.19. LC/MS (ESI) m/z: 431 (M+1), 861 (2M+1).
29. Compound 4f. To a solution of the 3f (1 eq) in anhydrous THF (30 mL/mmol) was added 4-
nitrophenylisocyanate (1 eq). The reaction mixture was stirred at room temperature overnight, 
concentrated. Silica cake was prepared in acetone and chromatographic separation on silica gel 
(EtOAc/CH2Cl2 = 1/30 to 1/5) gave the crude solids which were further recrystallized in acetone 
to give the expected compound as yellow solids. Yield: 7%. 1H NMR (acetone-d6, 400 MHz), δ 
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30. Compound 4h. To a solution of the 3h (1 eq) in anhydrous THF (30 mL/mmol) was added 4-
nitrophenylisocyanate (1 eq). The reaction mixture was stirred at room temperature overnight, 
concentrated. Silica cake was prepared in acetone and chromatographic separation on silica gel 
(EtOAc/CH2Cl2 = 1/30 to 1/5) gave the crude solids which were further recrystallized in acetone 
to give the expected compound as light yellow solids. Yield: 13%. 1H NMR (acetone-d6, 400 
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31. Compound 4l. To a solution of the 3l (1 eq) in anhydrous THF (30 mL/mmol) was added 4-
nitrophenylisocyanate (1 eq). The reaction mixture was stirred at room temperature overnight, 
concentrated. Silica cake was prepared in acetone and chromatographic separation on silica gel 
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m/z: 413 (M+1), 825 (2M+1).
32. Boehlein SK; Richards NG; Schuster SM Glutamine-dependent nitrogen transfer in Escherichia 
coli asparagine synthetase B. Searching for the catalytic triad. Journal of Biological Chemistry 
1994, 269, 7450–7457. [PubMed: 7907328] 
33. Kim P; Zhang L; Manjunatha UH; Singh R; Patel S; Jiricek J; Keller TH; Boshoff HI; Barry CE; 
Dowd CS Structure–Activity Relationships of Antitubercular Nitroimidazoles. 1. Structural 
Features Associated with Aerobic and Anaerobic Activities of 4- and 5-Nitroimidazoles. Journal of 
Medicinal Chemistry 2009, 52, 1317–1328. [PubMed: 19209889] 
34. San Jose G; Jackson ER; Uh E; Johny C; Haymond A; Lundberg L; Pinkham C; Kehn-Hall K; 
Boshoff HI; Couch RD; Dowd CS Design of potential bisubstrate inhibitors against 
Mycobacterium tuberculosis (Mtb) 1-deoxy-d-xylulose 5-phosphate reductoisomerase (Dxr)-
evidence of a novel binding mode. MedChemComm 2013, 4, 1099–1104. [PubMed: 23914289] 
35. Yendapally R; Hurdle JG; Carson EI; Lee RB; Lee RE N-Substituted 3-Acetyltetramic Acid 
Derivatives as Antibacterial Agents. Journal of Medicinal Chemistry 2008, 51, 1487–1491. 
[PubMed: 18281930] 
36. San Jose G; Jackson ER; Haymond A; Johny C; Edwards RL; Wang X; Brothers RC; Edelstein 
EK; Odom AR; Boshoff HI; Couch RD; Dowd CS Structure-Activity Relationships of the 
MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from 
Mycobacterium tuberculosis and Yersinia pestis. ACS Infectious Diseases 2016, 2, 923–935. 
[PubMed: 27676224] 
Wang et al. Page 7
Bioorg Med Chem Lett. Author manuscript; available in PMC 2018 October 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Two-step reaction catalyzed by NAD+ synthetase.
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Figure 2. 
Structures and bioactivities of known NadE inhibitors.14, 16, 19, 20
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Figure 3. 
Compound 4l (R = 4-H) docked into Mtb NadE (PDB: 3DLA). (A) The green ribbon 
represents NadE. The ligand and selected protein residues are colored by atom type, and 
hydrogen bonding is represented by dashed red lines. (B) Using the same NadE orientation, 
the surface of the enzyme is colored to show the degree of hydrophobicity (darker red 
indicates more hydrophobic character). Ring A (circled) is shown going into the ammonia 
tunnel at its entrance.
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Figure 4. 
Structure of parent compound 5824 and the analogs prepared in this work.
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Scheme 1. 
Reagents and conditions: a) pyridine, 4-AcNHPhSO2Cl; b) HCl; c) 4-NO2PhNCO
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Table 1.
Sequence identity between NadE synthetase homologs from Mtb, B. subtilis and B. anthracis
Sequence Identity (%) B. subtilisNadE
B. anthracis
NadE
Mtb NadE
(C-term
Synthetase
domain)
Mtb NadE C-term Synthetase domain 36.6
B. subtilis NadE 88.6
B. anthracis NadE 34.4
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Table 2.
Mtb NadE inhibition and growth inhibition of urea-sulfonamide analogs
Compound R
Mtb NadE
IC50 (μM)
Gln-dependent
Mtb NadE
IC50 (μM)
NH3-dependent
Mtb MIC
(μg/mL)
7H9
Mtb MIC
(μg/mL)
GAST-Fe
4a 4-OH 160 ± 20 37 50
4b 3-CF3, 4-NO2 190 ± 10 100 50
4c 3-NO2 170 ± 20 25 12.5
4d 4-OMe 130 ± 10 >200 25 50
4e 4-F 170 ± 20 19 25
4f 4-NO2 90 ± 5 >200 37 25
4g 4-CN 190 ± 10 37 37
4h 3-CF3 130 ± 20 >200 37 50
4i 3,4-diCl 1000 ± 300 25 50
(582420)
4j 4-I 370 ± 10 37 50
4k 4-Cl 520 ± 100 25 37
4l H 125 ± 5 >200 75 12.5
INH 0.05 0.03
Mtb = Mycobacterium tuberculosis; IC50 = inhibitor concentration resulting in 50% enzyme inhibition; MIC = minimum inhibitory concentration; 
7H9 = rich media; GAST = minimal media; INH= isoniazid
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